900 related articles for article (PubMed ID: 20132203)
1. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service.
Cardozo L; Thorpe A; Warner J; Sidhu M
BJU Int; 2010 Aug; 106(4):506-14. PubMed ID: 20132203
[TBL] [Abstract][Full Text] [Related]
2. A cost-utility analysis of once daily solifenacin compared to tolterodine in the treatment of overactive bladder syndrome.
Speakman M; Khullar V; Mundy A; Odeyemi I; Bolodeoku J
Curr Med Res Opin; 2008 Aug; 24(8):2173-9. PubMed ID: 18565239
[TBL] [Abstract][Full Text] [Related]
3. Solifenacin in the treatment of overactive bladder syndrome in Italian patients: pharmacoeconomic evaluation.
Pradelli L; Iannazzo S
J Med Econ; 2009 Mar; 12(1):25-35. PubMed ID: 19450062
[TBL] [Abstract][Full Text] [Related]
4. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service.
Warner JL
BJU Int; 2010 Aug; 106(4):586. PubMed ID: 20653664
[No Abstract] [Full Text] [Related]
5. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I
Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
[TBL] [Abstract][Full Text] [Related]
6. Economic impact of extended-release tolterodine versus immediate- and extended-release oxybutynin among commercially insured persons with overactive bladder.
Varadharajan S; Jumadilova Z; Girase P; Ollendorf DA
Am J Manag Care; 2005 Jul; 11(4 Suppl):S140-9. PubMed ID: 16161387
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of solifenacin versus oxybutynin immediate-release in the treatment of patients with overactive bladder in the United Kingdom.
Hart WM; Abrams P; Munro V; Retsa P; Nazir J
J Med Econ; 2013 Oct; 16(10):1246-54. PubMed ID: 23885660
[TBL] [Abstract][Full Text] [Related]
8. Treatment of overactive bladder: a model comparing extended-release formulations of tolterodine and oxybutynin.
Perfetto EM; Subedi P; Jumadilova Z
Am J Manag Care; 2005 Jul; 11(4 Suppl):S150-7. PubMed ID: 16161388
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of percutaneous tibial nerve stimulation versus extended release tolterodine for overactive bladder.
Chen HW; Bercik RS; Werner EF; Thung SF
J Urol; 2012 Jan; 187(1):178-84. PubMed ID: 22100006
[TBL] [Abstract][Full Text] [Related]
10. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
[TBL] [Abstract][Full Text] [Related]
11. Treatment outcomes in the STAR study: a subanalysis of solifenacin 5 mg and tolterodine ER 4 mg.
Chapple CR; Fianu-Jonsson A; Indig M; Khullar V; Rosa J; Scarpa RM; Mistry A; Wright DM; Bolodeoku J;
Eur Urol; 2007 Oct; 52(4):1195-203. PubMed ID: 17574730
[TBL] [Abstract][Full Text] [Related]
12. Which anticholinergic drug for overactive bladder symptoms in adults.
Madhuvrata P; Cody JD; Ellis G; Herbison GP; Hay-Smith EJ
Cochrane Database Syst Rev; 2012 Jan; 1():CD005429. PubMed ID: 22258963
[TBL] [Abstract][Full Text] [Related]
13. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
[TBL] [Abstract][Full Text] [Related]
14. Impact of solifenacin on resource utilization, work productivity and health utility in overactive bladder patients switching from tolterodine ER.
Zinner N; Noe L; Rasouliyan L; Marshall T; Seifeldin R
Curr Med Res Opin; 2008 Jun; 24(6):1583-91. PubMed ID: 18423103
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of solifenacin flexible dosing in patients with overactive bladder symptoms in four Nordic countries.
Milsom I; Axelsen S; Kulseng-Hansen S; Mattiasson A; Nilsson CG; Wickstrøm J
Acta Obstet Gynecol Scand; 2009; 88(6):693-9. PubMed ID: 19384673
[TBL] [Abstract][Full Text] [Related]
16. Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder.
Ko Y; Malone DC; Armstrong EP
Pharmacotherapy; 2006 Dec; 26(12):1694-702. PubMed ID: 17125433
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of anti-muscarinic agents for the treatment of overactive bladder.
Armstrong EP; Malone DC; Bui CN
J Med Econ; 2012; 15 Suppl 1():35-44. PubMed ID: 22998646
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of extended-release formulations of oxybutynin and tolterodine for the management of urge incontinence.
Hughes DA; Dubois D
Pharmacoeconomics; 2004; 22(16):1047-59. PubMed ID: 15524493
[TBL] [Abstract][Full Text] [Related]
19. Medical costs after initiation of drug treatment for overactive bladder: effects of selection bias on cost estimates.
Nitz NM; Jumadilova Z; Darkow T; Frytak JR; Bavendam T
Am J Manag Care; 2005 Jul; 11(4 Suppl):S130-9. PubMed ID: 16161386
[TBL] [Abstract][Full Text] [Related]
20. Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial.
Herschorn S; Stothers L; Carlson K; Egerdie B; Gajewski JB; Pommerville P; Schulz J; Radomski S; Drutz H; Barkin J; Paradiso-Hardy F
J Urol; 2010 May; 183(5):1892-8. PubMed ID: 20303119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]